Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, m... Read More
Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, 2-Part Study to Determine the Effect of Injection Site on the Relative Bioavailability ... Read More
Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab... Read More
Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety o... Read More
Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'A Phase Ib, Open-Label, Multicenter Study of EBC-129 Combined With Osimertinib in Patients With Ad... Read More
Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Com... Read More
Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared w... Read More
Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemothera... Read More
Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'A longitudinal study to investigate innate immune reprogramming following Herpes Zoster vaccinatio... Read More
Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'Phase I/II study of Mezigdomide and Elranatamab for relapsed/refractory multiple myeloma patients ... Read More